|Tuesday, 4 October 2016, 08:00 HKT/SGT|
Paris, France and Cambridge, Massachusetts, USA, Oct 4, 2016 - (ACN Newswire) - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that it has strengthened its U.S. leadership team with the appointments of Dr. Mihail Obrocea as the Head of U.S. Clinical Development and Noel Kurdi as the Director of Investor Relations.
These high level profiles will contribute to reinforce Nanobiotix's presence in the US by strengthening its clinical development and by leveraging US investors potential to continue the growth of the Company.
In the US, Nanobiotix has successfully filed its Investigational New Drug application (IND) for NBTXR3 for the treatment of prostate cancer and plans to initiate a Phase I/II trial in three U.S. based oncology sites. In parallel, the Company continues to advance the development its lead product in multiple oncology indications across the world.
Nanobiotix incorporated an affiliate in Cambridge in 2014, and opens a new office today in New York City, in order to increase the Company's visibility and be accessible to the financial community.
Dr. Mihail Obrocea joined Nanobiotix from U.S.-based SFJ Pharmaceuticals Group, where he held the position of Vice President of Clinical & Medical Affairs. Previously, he served as Project Director and Oncology Clinical Lead at AbbVie Biotherapeutics Corp., leading multiple Phase I and II oncology and hematology clinical trials. He also held the position of Vice President and Head of Clinical Development Oncology at MannKind Corp. where he brought two cancer vaccines programs into the clinical stages. He has held clinical leadership positions at Sigma-Tau Research and MedImmune. Dr. Obrocea earned his M.D. from the School of Medicine and Pharmacy in Bucharest, Romania. He completed an internal medicine residency at Yale University School of Medicine in Connecticut and completed a hematology / oncology fellowship at Dartmouth Medical School in New Hampshire.
Noel Kurdi joined Nanobiotix from the Trout Group & Trout Capital, where she served as a Senior Associate, providing strategic investor relations counsel to US based and multinational biotech companies seeking access to the US and international capital markets. Previously, Kurdi worked in institutional equity sales and research at Brean Capital, LLC, and held capital markets, business development and investor relations roles at AIG investments. She earned her M.B.A. in finance and marketing from Fordham University and a B.B.A. in international business and marketing from George Washington University.
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients.
NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration.
Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma, head and neck cancer, prostate cancer, rectal cancer (PharmaEngine) and liver cancers (HCC and liver metastases). The Company has filed in August 2016 for market approval (CE Marking) in Europe for its lead product NBTXR3. The Company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.
Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company Headquarter is based in Paris, France. Affiliate in Cambridge, United States. For more information, please visit www.nanobiotix.com
Head of Communication and Public Affairs
+33 (0)1 40 26 07 55
France - NewCap
+33 (0)6 88 20 35 59
EU Outside France - Instinctif Partners
Melanie Toyne Sewell
+44 (0) 207 457 2020
United States - The Ruth Group
Kirsten Thomas / Chris Hippolyte
+1 508-280-6592 / +1 646-536-7023
This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix filed with the French Financial Markets Authority (Autorite des Marches Financiers) under number D.16-0732 on July 22, 2016 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country.
Oct 4, 2016 08:00 HKT/SGT
Topic: Press release summary
Sectors: Science & Research, BioTech
From the Asia Corporate News Network
Copyright © 2017 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|May 18, 2017 14:00 HKT/SGT|
Nanobiotix Announces First Positive Human Data Showing That NBTXR3 Could Become a Backbone in Immuno-Oncology|
|Apr 29, 2017 01:00 HKT/SGT|
Nanobiotix: 2016 Annual Results|
|Apr 4, 2017 14:50 HKT/SGT|
Nanobiotix Expands Its Clinical Development in Head and Neck Cancer and Immuno-Oncology|
|Mar 24, 2017 07:00 HKT/SGT|
NANOBIOTIX: The Independent Data Monitoring Committee Recommends the Continuation of the Ongoing Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma|
|Mar 7, 2017 15:50 HKT/SGT|
Nanobiotix to Present Preclinical Data on Nanoparticle Radioenhancer NBTXR3 at the AACR Annual Meeting 2017|
|Feb 7, 2017 16:30 HKT/SGT|
Nanobiotix Appoints Senior Executive from Pharmaceutical Industry, as Chief Operating Officer|
|Feb 1, 2017 08:00 HKT/SGT|
NANOBIOTIX: 2016 Review and 2017 Anticipated Milestones|
|Dec 15, 2016 08:00 HKT/SGT|
Nanobiotix Reports Positive Phase I/II Preliminary Data on Feasibility and Safety of NBTXR3 in Liver Cancers Trial|
|Nov 29, 2016 08:00 HKT/SGT|
Nanobiotix Provides Update on Global Development of Lead Product NBTXR3|
|Nov 14, 2016 15:20 HKT/SGT|
Nanobiotix Presents NBTXR3 Preclinical Data Demonstrating Its Potential Usage as In Situ Vaccine for Cancer at the Society for Immunotherapy of Cancer Annual Meeting|
|More news >>|